Your browser doesn't support javascript.
Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
Liu, Mei-Qin; Jiang, Ren-Di; Guo, Jing; Chen, Ying; Yang, Dong-Sheng; Wang, Xi; Lin, Hao-Feng; Li, Ang; Li, Bei; Hu, Ben; Wang, Ze-Jun; Yang, Xing-Lou; Shi, Zheng-Li.
  • Liu MQ; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Jiang RD; University of Chinese Academy of Sciences, Beijing, China.
  • Guo J; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Chen Y; University of Chinese Academy of Sciences, Beijing, China.
  • Yang DS; Wuhan Institute of Biological Products Co. Ltd., Jiangxia District, Wuhan, China.
  • Wang X; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Lin HF; University of Chinese Academy of Sciences, Beijing, China.
  • Li A; Wuhan Institute of Biological Products Co. Ltd., Jiangxia District, Wuhan, China.
  • Li B; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Hu B; University of Chinese Academy of Sciences, Beijing, China.
  • Wang ZJ; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Yang XL; University of Chinese Academy of Sciences, Beijing, China.
  • Shi ZL; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
J Virol ; 96(8): e0016922, 2022 04 27.
Article in English | MEDLINE | ID: covidwho-1765080
ABSTRACT
Severe acute respiratory syndrome coronavirus (SARS-CoV-1) and SARS-CoV-2 are highly pathogenic to humans and have caused pandemics in 2003 and 2019, respectively. Genetically diverse SARS-related coronaviruses (SARSr-CoVs) have been detected or isolated from bats, and some of these viruses have been demonstrated to utilize human angiotensin-converting enzyme 2 (ACE2) as a receptor and to have the potential to spill over to humans. A pan-sarbecovirus vaccine that provides protection against SARSr-CoV infection is urgently needed. In this study, we evaluated the protective efficacy of an inactivated SARS-CoV-2 vaccine against recombinant SARSr-CoVs carrying two different spike proteins (named rWIV1 and rRsSHC014S, respectively). Although serum neutralizing assays showed limited cross-reactivity between the three viruses, the inactivated SARS-CoV-2 vaccine provided full protection against SARS-CoV-2 and rWIV1 and partial protection against rRsSHC014S infection in human ACE2 transgenic mice. Passive transfer of SARS-CoV-2-vaccinated mouse sera provided low protection for rWIV1 but not for rRsSHC014S infection in human ACE2 mice. A specific cellular immune response induced by WIV1 membrane protein peptides was detected in the vaccinated animals, which may explain the cross-protection of the inactivated vaccine. This study shows the possibility of developing a pan-sarbecovirus vaccine against SARSr-CoVs for future preparedness. IMPORTANCE The genetic diversity of SARSr-CoVs in wildlife and their potential risk of cross-species infection highlight the necessity of developing wide-spectrum vaccines against infection of various SARSr-CoVs. In this study, we tested the protective efficacy of the SARS-CoV-2 inactivated vaccine (IAV) against two SARSr-CoVs with different spike proteins in human ACE2 transgenic mice. We demonstrate that the SARS-CoV-2 IAV provides full protection against rWIV1 and partial protection against rRsSHC014S. The T-cell response stimulated by the M protein may account for the cross protection against heterogeneous SARSr-CoVs. Our findings suggest the feasibility of the development of pan-sarbecovirus vaccines, which can be a strategy of preparedness for future outbreaks caused by novel SARSr-CoVs from wildlife.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Inactivated / Coronavirus Infections / Cross Protection / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Virol Year: 2022 Document Type: Article Affiliation country: Jvi.00169-22

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Inactivated / Coronavirus Infections / Cross Protection / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Virol Year: 2022 Document Type: Article Affiliation country: Jvi.00169-22